Jon Napitupulu

Neurogene Inc. announced positive interim clinical data from its Phase 1/2 open-label trial of NGN-401 gene therapy for Rett...

A Phase III trial, WAYPOINT, has yielded positive results for AstraZeneca and Amgen’s TEZSPIRE (tezepelumab) in treating chronic rhinosinusitis...

Sarepta Therapeutics reported strong third-quarter 2024 financial results, marked by a significant revenue increase and positive net income. Net...

Janux Therapeutics, a clinical-stage biopharmaceutical company, recently announced its third-quarter 2024 financial results and provided a business update. The...

Gilead Sciences reported third-quarter solid 2024 financial results, with a 7% year-over-year increase in total product sales, reaching $7.5...

Viridian Therapeutics, a Nasdaq-listed biopharmaceutical company (VRDN), granted stock options to six new employees on November 1, 2024. These...

The connected drug delivery devices market, currently valued at $4.4 billion, is predicted to experience substantial growth, with a...

The global market for Alzheimer’s drugs is poised for significant growth, projected to reach $9.2 billion by 2030, reflecting...

Acadia Pharmaceuticals has finalized an agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for $150 million....

Exact Sciences Corp. (Nasdaq: EXAS), a prominent cancer screening and diagnostics company, reported third-quarter 2024 revenue of $709 million,...